Flexion Therapeutics (FLXN) Tops Q1 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Flexion Therapeutics (FLXN) Tops Q1 EPS by 13c

Flexion Therapeutics Reports First-Quarter 2015 Financial Results

May 7, 2015 4:05 PM EDT

Key Highlights

Announced a U.S. Department of Defense (DoD) grant worth approximately $2 million to conduct a Phase 2 clinical trial to study lead compound FX006 in active military and medically retired veterans with post-traumatic osteoarthritis (OA) Advanced FX006 by initiating Phase 3 clinical trial on schedule and completing enrollment in pivotal Phase 2b clinical trial Appointed Scott Canute, former President of Global Manufacturing at Eli Lilly and Company and subsequently at Genzyme Corporation, as new Board member

BURLINGTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.... More